# Neurocrine Biosciences Inc (NBIX) — Stock CV

Neurocrine Biosciences Inc is a $14.5B healthcare company. Revenue grew 34.4% over the last year, it keeps 21¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 20.5× earnings — near the lowest of its own history.

> Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.

## Identity

- **Ticker**: NBIX
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: SAN DIEGO, CA
- **Employees**: 2 500
- **Website**: https://www.neurocrine.com
- **Market cap**: $14.5B
- **Last price**: $142.44
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $3.37B
- **Net income**: $706M
- **Free cash flow**: $866M
- **Net cash**: $1.01B
- **P/E**: 20.5
- **Revenue growth (YoY)**: 34.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 77 |
| Growth | 81 |
| Profitability | 85 |
| Health | 86 |
| Quality | 60 |
| Moat | 63 |

## Qualifications (beginner checklist) — 10 of 10 passed

- [x] Revenue growing — +34.4% YoY
- [x] Profitable — $706M TTM
- [x] Profit growing — +44.0% YoY
- [x] Generates cash — $866M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $14.5B market cap
- [x] Not printing shares — +4.8% shares over ~5y
- [x] Proven track record — 8/10 profitable years
- [x] Financially stable — Altman Z 6.2 — safe
- [x] Valuation not extreme — P/E 20.5

## Experience (career milestones)

- **FY2025** — Best year on record: $479M net income
- **FY2020** — Revenue crossed $1B: $1.05B for the year
- **FY2018** — Turned profitable: $21.1M net income after a loss year
- **FY2018** — Positive free cash flow every year since: 8-year streak
- **1992** — Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992

## Strengths

- High gross margin (98.0%)
- Strongly profitable — 20.9% net margin
- Revenue growing 34.4% year over year
- Strong cash conversion — FCF is 25.7% of revenue
- Net cash position after subtracting debt from cash

## Watch-outs

- Loss-making in 2 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $1.13B | $89.6M | $233M |
| FY2022 | $1.49B | $155M | $323M |
| FY2023 | $1.89B | $250M | $362M |
| FY2024 | $2.36B | $341M | $557M |
| FY2025 | $2.86B | $479M | $749M |

---

Source: https://stockcv.com/NBIX — derived from company filings; may be delayed or incomplete. Information, not investment advice.